Date: 2023.01.22; update: 2023.02.13; update: 2023.02.23; update: 2023.04.27

Field Safety Notice Belzer UW[®] Cold Storage Solution; Belzer MPS[®] & StoreProtect[®]

For Attention of*: Distributors, Importers, Hospitals, Health Care Professionals

Contact details of local representative (name, e-mail, telephone, address etc.)*

Legal Manufacturer:

Carnamedica Sp. z o.o. 21/U6 Olszynki Grochowskiej St. 04-281 Warsaw Poland e-mail: <u>vigilance@carnamedica.com</u>

Distributors of Belzer UW[®] Cold Storage Solution, Belzer MPS[®]:

Bridge to Life Europe Ltd. LU 311 The Light Bulb 1 Filament Walk London SW18 4GQ Phone: +44(0)20 3411 8326 Fax: +44 (0)20 3004 1103 https://bridgetolife.eu/contact-bridge-to-life-ltd/

Bridge to Life Ltd. Logistics & Ordering: 128 Suber Rd. Suite A Columbia, SC 29210; USA

Distributor of StoreProtect^{®,} Belzer MPS[®] (Poland):

Infusion 21/U6 Olszynki Grochowskiej St. 04-281 Warsaw Poland e-mail: <u>vigilance@carnamedica.com</u>


Field Safety Notice (FSN) Belzer UW[®] Cold Storage Solution; Belzer MPS[®] & StoreProtect[®]

	1. Information on Affected Devices*
1.	1. Device Type(s)*
	 Belzer UW[®] Cold Storage Solution (University of Wisconsin Solution) Container with perfusion and preservation solution for organs intended for transplantation Belzer MPS[®] (UW Machine Perfusion Solution) Container with perfusion and preservation solution for organs intended for transplantation
	• StoreProtect [®] Container with perfusion and preservation solution for organs intended for transplantation
1.	2. Commercial name(s)*
	 Belzer UW[®] Belzer MPS[®] StoreProtect[®]
1.	3. Unique Device Identifier(s) (UDI-DI)
	See Appendix A to this FSN.
1.	 4. Primary clinical purpose of device(s)* • Belzer UW[®]
	Belzer UW [®] Cold Storage Solution (University of Wisconsin Solution) is a clear to light yellow, sterile, non-pyrogenic solution intended for the flushing and the hypothermic storage of organs (kidney, liver, pancreas) or other organs at the time of organ removal from the donor, in preparation for storage, transportation and eventual transplantation into the recipient.
	• Belzer MPS® Belzer MPS® (UW Machine Perfusion Solution) perfusion solution is a clear to slightly yellow, sterile, non-pyrogenic, non-toxic solution for the in-vitro flushing and temporary continuous hypothermic machine perfusion of organs during their storage, transportation, until transplantation into a recipient.
	• StoreProtect [®] StoreProtect [®] is a clear to light yellow, sterile, non-pyrogenic solution intended for the flushing and the hypothermic storage of organs (kidney, liver, pancreas) or other organs at the time of organ removal from the donor, in preparation for storage, transportation and eventual transplantation into the recipient.
1.	5. Device Model/Catalogue/part number(s)*
	See Appendix A to this FSN.
1.	6. Software version Not applicable
1.	7. Affected serial or lot number range
••	See Appendix A to this FSN.
1.	8. Associated devices
	Not applicable

	2. Reason for Field Safety Corrective Action (FSCA)*
2.	 Description of the product problem* Carnamedica Sp. z o.o., with this Field Safety Notice is initiating a voluntary suspension to supply for the sterile Belzer UW[®], Belzer MPS[®] and StoreProtect[®] (the list of reference codes and LOT numbers is included in the Appendix A), effective immediately. Carnamedica has determined the following issues related to these devices: leaking within the solution bag overwrap, turbidity and discoloration; visible particulates. The defects are immediately identifiable upon product acceptance prior to the use of the solution. The affected devices were shipped during the time frame of 12.2021 – 11.2022.
2.	2. Hazard giving rise to the FSCA*
	A damaged or leaking bag could result in microbial contamination of the sterile solution path due to lose of the sterile barrier. The turbidity and obvious intense discoloration is an indication of microbial contamination. This may predispose patients to peritonitis, infection, sepsis and failure to graft. Additional potential hazards that may result include delay in therapy.
	may be a potential risk of delayed graft function due to obliteration of some small vessels.
	The risk is mitigated by the end user during the organs' preparation procedure according to the Instructions for Use (IFU), section PREPARATION. It is an obligatory standard for the end user to check each container that is used for presence of leakage/ discoloration or foreign particles, before the solution is administrated into the organ. In case that the solution contains any visible particles/ discoloration/ leakage, the product must be discarded and cannot be used for the patient.
2.	3. Probability of problem arising
	There have been no serious injuries associated with leakage/ discoloration or particles that were reported in the accessible literature. There are a handful of reports that cite near-miss situations, without actual injury, and the majority are discussing theoretical adverse events based on common medical knowledge but without real life proof of occurrence. It implies that the probability that the devices create hazardous situation leading to an injury is very low/ unlikely. The devices are used by the Health Care Professional user.
2.	4. Predicted risk to patient/users
	Based on the internal and external investigations, the Medical Assessment part of the Health Hazard Evaluation (HHE) where the risk involved is theoretical and given that no identifiable studies relating to leakage/ discoloration or particles incidents leading to an adverse event are evident, and the lack any reports to Carnamedica of injury related to that. The risk is mitigated by the end user during the organs' preparation procedure and should not to cause adverse health consequences. All risks were identified by the manufacturer within the risk analysis and the information about such remaining risks is incorporated into the Instruction for Use (IFU).
2.	5. Further information to help characterise the problem
	Leakages and turbidity/ discoloration occur when the sterile barrier of the product is lost. Several factors can cause these defects: the EVA bag micro-sealing issue, the EVA bag injection port issue, the aseptic process issue. These issues affect only the individual affected bags, not the entire batch (LOT). The original issue is related to the individual EVA bags and can contribute to the aseptic process and result in microbiological contamination.
	The presence of visible particles in the solution is the result of overheating caused by failure to meet the manufacturer's specified transport/ storage temperature in the supply chain.

	This issue is limited to Belzer UW [®] and Belzer MPS [®] solutions caused by improper product's handling and distribution.
2.	6. Background on Issue
	Customers reported an increase number of defects related to the leakages, discoloration and particles in the solutions before the use. None of the complaints report any patient adverse events.
2.	7. Other information relevant to FSCA
	Stop any further use of the affected devices.

d the
ining
ected s.



Actions related to the distributors/ importers:

- 1. **Conduct** a physical count and **record** the data on the Distributor/Importer Reply Form (in case of the distributors/ importers) attached to this Notice.
- 2. Place reviewed product into quarantine and return to the manufacturer.
- 3. Return the Distributor/Importer Reply Form to:
 - your local representative/ distributor (in country BTL representative: <u>f.harvey@b2ll.com</u> and <u>m.harper@b2ll.com</u>);
 - or via e-mail to vigilance@carnamedica.com.
 - This is important to complete even, if you have no affected product on hand. Please ensure the form contains a contact name and signature.
- 4. Contact your local representative/ distributor (in country BTL representative or <u>https://bridgetolife.eu/contact-bridge-to-life-ltd/)</u> or Carnamedica's Service on <u>office@carnamedica.com</u> to understand how to obtain a credit note against affected product and organize the product's return.
- 5. Maintain awareness of this Notice until all affected product has been inspected/ destroyed.
- 6. **Share** this Notice with anyone who needs to be informed in your facility, or in any facility where potentially affected devices may have been transferred.
- For any questions about the recall process, please contact your local representative/ distributor (in country BTL representative Mr. Mark Harper – Bridge to Life QA Director – <u>m.harper@B2LL.com) or Carnamedica at vigilance@carnamedica.com.</u>

Actions related to the Health Care Professionals:

- 1. **Conduct** a physical count and **record** the data on the Customer Reply Form (in case of the hospitals/ clinics/ etc.) attached to this Notice.
- Perform and additional visual inspections according to the Appendix B to identify bags of solution that may represent leaking, discoloration, and contamination with particles prior to use of product. Before any use of the product, check their condition according to the IFU (Instructions for Use), section PREPARATION.
- 3. **Dispose** of the affected products through waste system, recycle packaging and **document** that on the Customer Reply Form attached to this Notice. If there is no possibility to dispose of the product in this way, you may return the product to local Customer representative through your normal means.
- 4. Return the Customer Reply Form to:
 - your local representative/ distributor (in country BTL representative: <u>f.harvey@b2ll.com</u> and <u>m.harper@b2ll.com</u>);
 - or via e-mail to vigilance@carnamedica.com.

This is important to complete even, if you have no affected product on hand. Please ensure the form contains a contact name and signature.

- 5. **Contact** your local representative/ distributor (in country BTL representative or <u>https://bridgetolife.eu/contact-bridge-to-life-ltd/)</u> or Carnamedica's Customer Service on <u>office@carnamedica.com</u> to understand how to obtain a credit note against affected product.
- 6. Maintain awareness of this Notice until all affected product has been inspected/ destroyed.
- 7. **Share** this Notice with anyone who needs to be informed in your facility, or in any facility where potentially affected devices may have been transferred.
- For any questions about this process, please contact your local representative/ distributor (in country BTL representative Mr. Mark Harper – Bridge to Life QA Director – <u>m.harper@B2LL.com) or</u> Carnamedica at <u>vigilance@carnamedica.com</u>.

	2. By when should the action be completed?	The action should be completed within 90 days from delivery of this Field Safety Notice.
--	--	--

3.	3.	Particular considerations fo	r:	
		Not applicable		
		Is follow-up of patients or re	eview of patients' previous resu	Its recommended?
3.		Is customer Reply Required yes, form attached specifying		Yes The Distributor/Importer Reply Form or Customer Reply Form should be completed and returned within 90 days from delivery of this Field Safety Notice.
3.	5.	Action Being Taken by	the Manufacturer*	
		There are no other lots involv after manufacture. Carnamedi	 ☑ On-site device mod □ IFU or labelling cha □ None a root cause investigation and take yed in that. Other lots were alread ca is voluntary taking this action. 	ange n immediate corrective action. dy inspected for the condition
3.	6.	By when should the action be completed?	The action should be comple delivery of this Notice.	eted within 90 days from
3.	7.	Is the FSN required to be co /lay user?	ommunicated to the patient	No
3.	8.		ovided additional information su professional user information le	
		No	•	

	4. Genera	Il Information*
4.	1. FSN Type*	Update
4.	2. For updated FSN, reference number and date of previous FSN	This is an update to the original FSN # 001.01.2023 issued on 22 Jan 2023. [2023.02.23] – a second update of this FSN. [2023.04.27] – a third update of this FSN.
4.	3. For Updated FSN, key new inform	ation as follows:
	products. This FSN has been extended wi visible growing infection at the injection po- infection caused by sealing issue with the [2023.02.23] A second update of this FSN additional stocks of products. The FSN ha (BWUC2000); 022522; 101822; 031122; 0 [2023.04.27] The third update of this FSN	based on the results of the 100% inspection of the s been extended with the new LOTs: 061022 022822. is the result of additional data from the supply chain. LOTs: 111822; 111522; 080922; 082322 (BUWC).

4.	4. Further advice or information already expected in follow-up FSN? *	Not planned yet
4.	5. If follow-up FSN expected, what is Not planned yet.	the further advice expected to relate to:
4.	6. Anticipated timescale for follow- up FSN	Not planned yet.
4.	 7. Manufacturer information (For contact details of local representative a. Company Name b. Address 	refer to page 1 of this FSN) Carnamedica Sp. z o.o. 21/U6 Olszynki Grochowskiej St.; 04-281 Warsaw; Poland
	c. Website address	www.carnamedica.com
4.	 The Competent (Regulatory) Authors communication to customers. * YES 	prity of your country has been informed about this
4.	9. List of attachments/appendices:	 Appendix A – list of product references, lots and UDI codes Appendix B – Instructions for the visual inspection Distributor/Importer Reply Form Customer Reply Form
4.	10. Name/Signature	Paweł Szczudło CEO Signature

 Transmission of this Field Safety Notice

 This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred.

 Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.

 Please report all device-related incidents to the manufacturer (vigilance@carnamedica.com), distributor or local representative , and the national Competent Authority if appropriate, as this provides important feedback.*

Note: Fields indicated by * are considered necessary for all FSNs. Others are optional.

1		list of product references, batche	s and ODI codes
Reference number	LOT number	Product's name	UDI-DI code
BUWC	010722	Belzer UW [®] Cold Storage Solutionl (University of Wisconsin Solution) 1L	(01) 5906874879221 (10) 010722 (17) 230707
BUWC	061022	Belzer UW [®] Cold Storage Solution (University of Wisconsin Solution) 1L	(01) 5906874879221 (10) 061022 (17) 231210
BUWC	081222	Belzer UW [®] Cold Storage SolutionI (University of Wisconsin Solution) 1L	(01) 5906874879221 (10) 081222 (17) 240212
BUWC	022422	Belzer UW [®] Cold Storage Solution (University of Wisconsin Solution) 1L	(01) 5906874879221 (10) 022422 (17) 230824
BUWC	030222	Belzer UW [®] Cold Storage SolutionI (University of Wisconsin Solution) 1L	(01) 5906874879221 (10) 030222 (17) 230902
BUWC	090122	Belzer UW [®] Cold Storage Solution (University of Wisconsin Solution) 1L	(01) 5906874879221 (10) 090122 (17) 240301
BUWC	030322	Belzer UW [®] Cold Storage SolutionI (University of Wisconsin Solution) 1L	(01) 5906874879221 (10) 030322 (17) 230903
BUWC	110922	Belzer UW [®] Cold Storage SolutionI (University of Wisconsin Solution) 1L	(01) 5906874879221 (10) 110922 (17) 240509
BUWC	021822	Belzer UW [®] Cold Storage SolutionI (University of Wisconsin Solution) 1L	(01) 5906874879221 (10) 021822 (17) 230818
BUWC	112122	Belzer UW [®] Cold Storage SolutionI (University of Wisconsin Solution) 1L	N/A
BUWC	101822	Belzer UW [®] Cold Storage SolutionI (University of Wisconsin Solution) 1L	N/A
BUWC	031122	Belzer UW [®] Cold Storage Solution (University of Wisconsin Solution) 1L	N/A
BUWC	022822	Belzer UW [®] Cold Storage Solution (University of Wisconsin Solution) 1L	N/A
BUWC	111822	Belzer UW [®] Cold Storage Solution (University of Wisconsin Solution) 1L	N/A
BUWC	111522	Belzer UW [®] Cold Storage Solution (University of Wisconsin Solution) 1L	N/A
BUWC	080922	Belzer UW [®] Cold Storage Solution (University of Wisconsin Solution) 1L	N/A
BUWC	082322	Belzer UW [®] Cold Storage Solution (University of Wisconsin Solution) 1L	N/A
BUWC2000		Belzer UW [®] Cold Storage Solution	(01) 5906874879238 (10)
	030722	(University of Wisconsin Solution) 2L	030722 (17) 230907
BUWC2000	010322	Belzer UW [®] Cold Storage Solution (University of Wisconsin Solution) 2L	(01) 5906874879238 (10) 010322 (17) 230703
BUWC2000	030422	Belzer UW [®] Cold Storage Solution (University of Wisconsin Solution) 2L	(01) 5906874879238 (10) 030422 (17) 230904
BUWC2000	030822	Belzer UW [®] Cold Storage Solutionl (University of Wisconsin Solution) 2L	(01) 5906874879238 (10) 030822 (17) 230908
BUWC2000	123021	Belzer UW [®] Cold Storage Solutionl (University of Wisconsin Solution) 2L	(01) 5906874879238 (10) 20211230 (17) 20230630
BUWC2000	030922	Belzer UW [®] Cold Storage Solutionl (University of Wisconsin Solution) 2L	(01) 5906874879221 (10) 030922 (17) 230909
BUWC2000	030122	Belzer UW [®] Cold Storage Solutionl (University of Wisconsin Solution) 2L	(01) 5906874879238 (10) 030122 (17) 230901
BUWC2000	082222	Belzer UW [®] Cold Storage Solution (University of Wisconsin Solution) 2L	N/A
BUWC2000	082322	Belzer UW [®] Cold Storage Solution (University of Wisconsin Solution) 2L	N/A
BUWC2000	061022	Belzer UW [®] Cold Storage Solutionl (University of Wisconsin Solution) 2L	N/A
BUWC2000	022522	Belzer UW [®] Cold Storage Solution (University of Wisconsin Solution) 2L	N/A
BMPSC	110822	Belzer MPS [®] (UW Machine Perfusion Solution) 1L	(01) 5906874879245 (10) 110822 (17) 240508
	1		

Appendix A – list of product references, batches and UDI codes

Rev 2: February 2020 FSN Ref: 001.01.2023


Reference number	LOT number	Product's name	UDI-DI code
BMPSC	121721	Belzer MPS [®] (UW Machine Perfusion Solution) 1L	(01) 5906874879245 (10) 20211217 (17) 20230617
BMPSC	121621	Belzer MPS [®] (UW Machine Perfusion Solution) 1L	(01) 5906874879245 (10) 20211216 (17) 20230616
SPRT	120822	StoreProtect [®] 1L	(01) 5906874879009 (10) 120822 (17) 240212


Appendix B – Visual inspection for the Health Care Professionals

We would appreciate your assistance in the following actions:

- 5. **Read** the "2.1. Description of the product problem" section of the attached FSN carefully to fully understand the issue involved.
- 6. Please immediately **examine** your inventory stock to determine if you have any remaining product in your possession (**see Appendix A to the FSN**).
- 7. Stop any further usage of the affected product.
- 8. The following illustrations are provided to help you identify the products and lots. Affected lots are identified by the reference number and lot number on the bag and case labels.

Bag labels






Rev 2: February 2020 FSN Ref: 001.01.2023

FSCA Ref: 001.01.2023

Case label



- 5. **Conduct** a physical count and **record** the data on the Customer Reply Form (in case of the hospitals/ clinics/ etc.) attached to the FSN.
- 6. **Perform** and additional visual inspections according to this Appendix to identify bags of solution that may represent leaking, discoloration, and contamination with particles prior to use of product.

Should you have any existing product from the lots above or identify any units of solution containing leakage, discoloration or signs of contamination take immediate action to quarantine and report this information.

Only fluid presenting a colourless appearance should be considered uncontaminated. Before any use of the product, check their condition according to the IFU (Instructions for Use), section **PREPARATION**.

UNCONTAMINATED BAG


Description:

The solution is a clear to slightly yellow, sterile. No leakages from the bag. The bag is properly labeled, clear and dry and free from moisture.

		-
		P
1	FI	
	NALLA LA DI NALLA LA DI	



CONTAMINATED BAG LEAKAGE Description: Picture of Leaking Bag **TURBICIDY/ DISCOLORATION Description:** Picture of the turbid/ discolored solution



- 7. **Dispose** of the affected products through waste system, recycle packaging and **document** that on the Customer Reply Form attached to this Notice. If there is no possibility to dispose of the product in this way, you may return the product to local Customer representative through your normal means.
- 8. Return the Customer Reply Form to:
 - your local representative/ distributor (in country BTL representative: <u>f.harvey@b2ll.com</u> and <u>m.harper@b2ll.com</u>);
 - or via e-mail to <u>vigilance@carnamedica.com</u>. This is important to complete <u>even, if you have no affected product on hand</u>. Please ensure the form contains a contact name and signature.
- Contact your local representative/ distributor (in country BTL representative or <u>https://bridgetolife.eu/contact-bridge-to-life-ltd/)</u> or Carnamedica's Customer Service on <u>office@carnamedica.com</u> to understand how to obtain a credit note against affected product.
- 10. Maintain awareness of this Notice until all affected product has been inspected/ destroyed.
- 11. **Share** this Notice with anyone who needs to be informed in your facility, or in any facility where potentially affected devices may have been transferred.
- For any questions about this process, please contact your local representative/ distributor (in country BTL representative Mr. Mark Harper Bridge to Life QA Director <u>m.harper@B2LL.com) or</u> Carnamedica at <u>vigilance@carnamedica.com</u>.

٠